PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis - Concepedia

Concepedia

Publication | Open Access

PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis

DOI Full Paper Access

10

Citations

0

References

2019

Year

Emmanuel Gonzalès, Ekkehard Sturm, Michael Stormon, Étienne Sokal, Winita Hardikar, Florence Lacaille, Dorota Gliwicz, Loreto Hierro, Thomas Jaecklin, Joan Gu,

Journal of Hepatology

No additional data available for this publication yet. Check back later!